Table 2.
Prevalence and logistic regression of sedative-hypnotic use
| Variables | BZD (N05CD) | Non-BZD (N05CF) | ||||
|---|---|---|---|---|---|---|
| Prevalence (%) | OR | 95% CI | Prevalence (%) | OR | 95% CI | |
| Age | ||||||
| 65–74 | 2.4 | 1.00 | – | 2.6 | 1.00 | – |
| 75–84 | 4.1 | 1.52*** | 1.41–1.65 | 3.9 | 1.31*** | 1.21–1.42 |
| ≥ 85 | 6.2 | 2.56*** | 2.28–2.87 | 4.0 | 1.43*** | 1.25–1.63 |
| Sex | ||||||
| Male | 3.8 | 1.00 | – | 3.3 | 1.00 | – |
| Female | 2.7 | 0.71*** | 0.65–0.76 | 3.0 | 0.96 | 0.89–1.04 |
| Insurance amount ($)* | ||||||
| Fixed premium | 4.0 | 1.49 | 0.93–2.37 | 3.8 | 2.30** | 1.32–4.01 |
| Dependent | 3.3 | 1.54 | 0.97–2.45 | 3.2 | 2.09** | 1.20–3.65 |
| < 640 (< 20,000 NTD) | 2.8 | 1.20 | 0.75–1.91 | 2.8 | 1.90* | 1.09–3.32 |
| 640–1280 (20,000–39,999 NTD) | 2.8 | 1.42 | 0.82–2.45 | 2.4 | 1.71 | 0.91–3.23 |
| ≥ 1281(≥40,000 NTD) | 2.0 | 1.00 | – | 1.4 | 1.00 | – |
| Charlson Comorbidity Index | ||||||
| 0 | 0.5 | 1.00 | – | 0.5 | 1.00 | – |
| 1 | 2.6 | 5.47*** | 4.59–6.51 | 2.7 | 5.43*** | 4.57–6.46 |
| 2 | 6.2 | 12.82*** | 10.72–15.34 | 5.7 | 11.63*** | 9.73–13.90 |
| 3 | 10.4 | 23.08*** | 19.32–27.58 | 9.8 | 21.33*** | 17.89–25.45 |
| Region | ||||||
| Northern | 3.2 | 0.59*** | 0.50–0.71 | 3.1 | 0.76** | 0.63–0.93 |
| Central | 3.2 | 0.59*** | 0.49–0.71 | 3.7 | 0.93 | 0.76–1.14 |
| Southern | 3.2 | 0.59*** | 0.50–0.71 | 2.8 | 0.69*** | 0.57–0.84 |
| Eastern | 5.3 | 1.00 | – | 4.0 | 1.00 | – |
| Urbanization | ||||||
| Urban | 3.2 | 0.82*** | 0.75–0.90 | 3.2 | 1.03 | 0.94–1.14 |
| Suburban | 3.3 | 0.97 | 0.87–1.08 | 3.4 | 1.12* | 1.00–1.25 |
| Rural | 3.3 | 1.00 | – | 2.9 | 1.00 | – |
| Total | 3.2 | 3.1 | ||||
*: p < 0.05
**: p < 0.01
***: p < 0.001